Atrial Fibrillation in Relationship to Plasma Biomarkers

  • STATUS
    Recruiting
  • End date
    Dec 27, 2024
  • participants needed
    300
  • sponsor
    Premedix Academy
Updated on 27 January 2021

Summary

The general objective of this study is to:

  1. To identify novel plasmatic biomarkers associated with prevalent/incident atrial fibrillation in patients with high risk for AF and stroke.
  2. To assess predictive ability of novel plasmatic biomarkers (especially apelin and miRNAs) on prevalent/incident atrial fibrillation in patients with high risk for AF and stroke.
  3. To validate predictive models from previous studies based on comorbidities, age, sex, BMI, NT-proBNP, FGF-23, IGF-1 and IGFBP-1 on prevalent/incident AF in patients with high risk for AF and stroke.

Description

Atrial fibrillation (AF) is the most common sustained arrhythmia, associated with an increased risk of stroke, heart failure, and mortality. Despite the high prevalence, AF may be asymptomatic and consequently unrecognized. Detection of asymptomatic AF is challenging as only a minority of the patients is diagnosed during standard examinations with a 12 - lead ECG or a 24h ECG Holter monitoring. Furthermore, prolonged ECG monitoring is costly and can be inconvenient for the patients. Documented AF causes 15% of ischemic strokes. However, approximately 25% of ischemic strokes is of an unknown etiology. It is believed that undetected asymptomatic AF is responsible for some of these strokes.

Plasmatic biomarkers might be of importance in the early diagnosis of AF. Several plasmatic biomarkers have been studied in order to find an association with AF. Cardiac biomarkers such as natriuretic peptides and high-sensitivity troponins are increased in patients with AF. A novel biomarker that is depending on left atrial stretching and ionotropic effects is apelin. In our previous research we discovered that apelin is associated with AF, negatively correlates with AF burden, but only in patients without reduced LVEF. Similarly, parameters reflecting thrombogenesis, such as Fibrinogen and fibrin D-dimer were also found to be associated with the arrhythmia. Other protein biomarkers have been studied in relation to AF incidence. Insulin-like growth factor-binding protein 1 (IGFBP-1) and Insulin-like growth factor 1 (IGF-1) have shown an association with higher risk of incident AF. Previous research also indicated Fibroblast growth factor 23 (FGF-23) to be associated with AF.

However, biomarkers, such as the inflammatory markers high-sensitivity CRP have shown conflicting results.

Finally, in the last years, circulating microRNAs emerged as a promising biomarker of AF, having important function in suppression of messenger RNA responsible for electric and structural remodeling of the left atria.

In our previous case-matched study we discovered that selected miRNAs were associated with paroxysmal AF.

Details
Condition Arrhythmia, Dysrhythmia, Arrhythmia, Atrial Fibrillation, Atrial Fibrillation, Atrial Fibrillation (Pediatric), Atrial Fibrillation (Pediatric), Dysrhythmia
Treatment Echocardiography, Peripheral blood samples for routine analysis including NT-proBNP and plasmatic biomarkers., ECG Holter monitor, Standardized Mini-Mental Status Exam (SMMSE)
Clinical Study IdentifierNCT04710745
SponsorPremedix Academy
Last Modified on27 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

General inclusion criteria
AGE > 50 years
No history of supraventricular arrhythmia
Sinus rhythm at inclusion
CHADSVASc score > 2 in men (> 3 in female)
More than 3 specific criteria for inclusion
Written informed consent is obtained before any study-related assessment is performed
Specific inclusion criteria
Age > 65
Age > 75
BMI > 30
Heart failure with preserved LVEF (according to ESC GL for HF)
Ischemic stroke
Left atrial diameter > 45mm
Chronic obstructive pulmonary disease
Arterial hypertension
PR interval > 200ms
History of MI or (objective evidence of) chronic coronary syndrome
Peripheral artery disease
Thyroid disease

Exclusion Criteria

History of any supraventricular or ventricular arrhythmia (excluding premature contractions and 1st degree AV block)
Therapy with anticoagulants at the time of inclusion
Acute coronary syndrome less than 1 month prior to inclusion
History of cardiac surgery
Diabetes mellitus type 2
Reduced LVEF (<50%)
Acute or decompensated heart failure at the time of inclusion
Cardiomyopathy
Systemic inflammatory disease or acute inflammatory disease
Active malignancy
Alcoholism ( 8 drinks/week)
Renal Disease (Dialysis/ transplant/ CrCl < 1ml/s)
Liver disease (cirrhosis/ transaminase > 3x ULT/ bilirubin > 2x ULT)
Severe or moderate mitral stenosis
Pregnancy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note